EuroBiotech:​​​ ​​​More​​​ ​​​Articles​​​ ​​​of​​​ ​​​Note

Newspapers

> PrEP Biopharm’s prophylactic against the common cold PrEP-001 missed the primary endpoint in two phase 2a trials. PrEP-001 is designed to empower the innate immune system to prevent viral infections of the respiratory tract. But the candidate failed to beat placebo in terms of patient assessed total symptom score in either trial. Johnson & Johnson and hVIVO led a £21 million ($26 million) Series A round in PrEP in 2015. Release

> Ferring and Ergomed reported positive top-line data from a phase 2 trial of their insomnia asset. Both doses of the drug met the primary endpoint. Ferring plans to pen additional partnerships to help take the program forward. Statement

> Kitov Pharmaceuticals revealed it is being formally investigated by the Israeli Securities Authority. The investigation relates to public disclosures about Kitov’s lead candidate, KIT-302. Israeli business newspaper Calcalist linked the case to disclosures made ahead of Kitov’s Nasdaq IPO. Statement I Calcalist (Hebrew)

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Oncopeptides filed for a SEK 650 million ($73 million) IPO in Sweden. The anticancer biotech plans to use half the cash to run a phase 3 trial of its peptidase potentiated alkylator in patients with multiple myeloma. A phase 2 trial of the drug in patients who had undergone two or more lines of treatment achieved an overall response rate of 40%. Release

> Auris Medical bought assets related to intranasal betahistine from Otifex Therapeutics. The deal adds a phase 1 candidate for the treatment of Meniere's disease and vestibular vertigo to Auris’ pipeline. Statement

> Kiadis Pharma began a phase 3 trial of ATIR101 in patients with acute leukemia. The 195-person trial will compare the efficacy of haploidentical allogeneic hematopoietic stem cell transplantation when complemented by either a single dose of ATIR101 or the post-transplant cyclophosphamide approach. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.